Sun Pharmaceutical Industries Limited — Sponsor Intelligence | 46 EU Trials

Filter these 46 trials by condition, phase, country and more.

Open in Search →

46 Registered trials

2 Recruiting

35 Completed trials

10 Countries active

4 Unique IMPs

100% Results reported

Other

Phase III: 4 Phase II/III: 1 Phase II: 3 Phase I (Other): 2 Other: 36

100%

35 of 35 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Axial spondyloarthritis 3 Crohn's disease 3 Colitis ulcerative 3

Top IMPs

TILDRAKIZUMAB 4 VIBOZILIMOD 2 ETANERCEPT 1 UTREGLUTIDE 1

All trials

46 total

A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Lisd… Pending

2024-517956-36-00 1 country
A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence stud… Pending

2025-521598-16-00 1 country
A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence stud… Pending

2025-522106-20-00 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover, bioavailability study comparing Bupropi… Pending

2025-523410-84-00 1 country
An open label, balanced, randomized, three treatment, three period, three sequence, single dose, crossover study to assess the effect of foo… Pending

2025-523411-11-00 Phase I (Other) 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametin… Pending

2025-524267-20-00 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Imatini… Pending

2025-524935-38-00 1 country
An open label, balanced, randomized, single dose, two-treatment, four period, two-sequence, crossover, fully replicate, bioequivalence study… Pending

2026-525420-22-00 1 country
An open label, balanced, randomized, single dose, two-treatment, two period, two-sequence, crossover, bioequivalence study comparing Fexofen… Pending

2026-525421-20-00 1 country
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study c… Recruiting

2025-520618-76-00 1 country
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTIPLE RISING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMA… Recruiting

2025-522097-36-00 Phase I (Other) 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ponatin… Ended

2025-524311-37-00 1 country
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study c… Ended

2025-520617-31-00 1 country
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis. Ended

2024-515672-12-00 Phase III 3 countries
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis. Ended

2022-501480-41-00 Phase III 7 countries TILDRAKIZUMAB
Study to see how good and safe Tildrakizumab is in children aged 6 to under 18 years of age with skin patches Ended

2023-504447-14-00 Phase II/III 4 countries ETANERCEPT; TILDRAKIZUMAB
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Maribav… Ended

2025-523487-21-00 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucrava… Ended

2025-523838-13-00 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucrava… Ended

2025-523839-18-00 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Lisdexa… Ended

2025-521224-29-00 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Clarith… Ended

2024-520153-21-00 1 country
A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupr… Ended

2024-516035-27-00 1 country
A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupr… Ended

2024-516034-35-00 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Tamsulo… Ended

2024-517642-34-00 1 country

Showing 1–24 of 46 trials

← All sponsors A–Z